H. Lundbeck A/S

PINK:HLBBF USA Drug Manufacturers - Specialty & Generic
Market Cap
$3.85 Billion
Market Cap Rank
#5879 Global
#3395 in USA
Share Price
$4.85
Change (1 day)
+0.00%
52-Week Range
$4.85 - $5.82
All Time High
$7.50
About

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more

H. Lundbeck A/S (HLBBF) - Total Assets

Latest total assets as of December 2025: $53.89 Billion USD

Based on the latest financial reports, H. Lundbeck A/S (HLBBF) holds total assets worth $53.89 Billion USD as of December 2025.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

H. Lundbeck A/S - Total Assets Trend (2004–2025)

This chart illustrates how H. Lundbeck A/S’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

H. Lundbeck A/S - Asset Composition Analysis

Current Asset Composition (December 2025)

H. Lundbeck A/S's total assets of $53.89 Billion consist of 23.7% current assets and 76.3% non-current assets.

Asset Category Amount (USD) % of Total Assets
Cash & Equivalents $0.00 6.4%
Accounts Receivable $4.54 Billion 8.4%
Inventory $4.46 Billion 8.3%
Property, Plant & Equipment $0.00 0.0%
Intangible Assets $28.71 Billion 53.3%
Goodwill $6.99 Billion 13.0%

Asset Composition Trend (2004–2025)

This chart illustrates how H. Lundbeck A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: H. Lundbeck A/S's current assets represent 23.7% of total assets in 2025, a decrease from 51.7% in 2004.
  • Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, down from 25.2% in 2004.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 14.0% in 2004.
  • Asset Diversification: The largest asset category is intangible assets at 53.3% of total assets.

H. Lundbeck A/S Competitors by Total Assets

Key competitors of H. Lundbeck A/S based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
USA $67.26 Billion
Dongwha Pharm.Co.Ltd
KO:000020
Korea ₩654.63 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥27.28 Billion
Yuhan Corp Preferred
KO:000105
Korea ₩3.05 Trillion
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
China CN¥4.97 Billion
Kotra Industries Bhd
KLSE:0002
Malaysia RM363.90 Million
Yuyu Pharma
KO:000220
Korea ₩202.42 Billion
Ildong Holdings Co Ltd
KO:000230
Korea ₩813.62 Billion

H. Lundbeck A/S - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.39 - 0.87

Moderate asset utilization - H. Lundbeck A/S generates 0.45x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: 3.80% - 16.98%

Solid ROA - For every $100 in assets, H. Lundbeck A/S generates $5.91 in net profit.

H. Lundbeck A/S - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.44 1.52 1.02
Quick Ratio 0.94 1.05 0.69
Cash Ratio 0.00 0.00 0.00
Working Capital $3.92 Billion $ 4.43 Billion $ 143.00 Million

H. Lundbeck A/S - Advanced Valuation Insights

This section examines the relationship between H. Lundbeck A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.59
Latest Market Cap to Assets Ratio 0.03
Asset Growth Rate (YoY) -5.4%
Total Assets $53.89 Billion
Market Capitalization $1.48 Billion USD

Valuation Analysis

Below Book Valuation: The market values H. Lundbeck A/S's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: H. Lundbeck A/S's assets decreased by 5.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for H. Lundbeck A/S (2004–2025)

The table below shows the annual total assets of H. Lundbeck A/S from 2004 to 2025.

Year Total Assets Change
2025-12-31 $53.89 Billion -5.42%
2024-12-31 $56.98 Billion +52.31%
2023-12-31 $37.41 Billion -0.12%
2022-12-31 $37.45 Billion +8.08%
2021-12-31 $34.65 Billion -3.82%
2020-12-31 $36.03 Billion +0.76%
2019-12-31 $35.76 Billion +55.39%
2018-12-31 $23.01 Billion +16.48%
2017-12-31 $19.76 Billion -2.25%
2016-12-31 $20.21 Billion -5.23%
2015-12-31 $21.32 Billion -16.82%
2014-12-31 $25.64 Billion +8.41%
2013-12-31 $23.65 Billion +9.67%
2012-12-31 $21.56 Billion +5.01%
2011-12-31 $20.53 Billion +14.05%
2010-12-31 $18.00 Billion +5.13%
2009-12-31 $17.13 Billion +35.86%
2008-12-31 $12.61 Billion +2.28%
2007-12-31 $12.33 Billion +5.98%
2006-12-31 $11.63 Billion +0.02%
2005-12-31 $11.63 Billion +1.04%
2004-12-31 $11.51 Billion --